The story may be unique in the history of prescription drug development. Vertex Pharmaceuticals Inc.’s protease inhibitor Incivek (telaprevir), only two years ago considered the top drug for treating chronic hepatitis C infection, is sputtering.
The drug, approved in March 2011, posted sales of nearly $1 billion in its first year on the market, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?